The inflammatory chemokines CCL2 and CCL5 in breast cancer - PubMed (original) (raw)
Review
. 2008 Aug 28;267(2):271-85.
doi: 10.1016/j.canlet.2008.03.018. Epub 2008 Apr 24.
Affiliations
- PMID: 18439751
- DOI: 10.1016/j.canlet.2008.03.018
Review
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Gali Soria et al. Cancer Lett. 2008.
Abstract
A causal role was recently attributed to inflammation in many malignant diseases, including breast cancer. The different inflammatory mediators that are involved in this disease include cells, cytokines and chemokines. Of these, many studies have addressed the involvement and roles of the inflammatory chemokines CCL2 (MCP-1) and CCL5 (RANTES) in breast malignancy. While minimally expressed by normal breast epithelial duct cells, both chemokines are highly expressed by breast tumor cells at primary tumor sites, indicating that CCL2 and CCL5 expression is acquired in the course of malignant transformation, and suggesting that the two chemokines play a role in breast cancer development and/or progression. Supporting this possibility are findings showing significant associations between CCL2 and CCL5 and more advanced disease course and progression. Furthermore, studies in animal model systems have shown active and causative roles for the two chemokines in this disease. In line with the tumor-promoting roles of CCL2 and CCL5 in breast cancer, the two chemokines were shown to mediate many types of tumor-promoting cross-talks between the tumor cells and cells of the tumor microenvironment: (1) they shift the balance at the tumor site between different leukocyte cell types by increasing the presence of deleterious tumor-associated macrophages (TAM) and inhibiting potential anti-tumor T cell activities; (2) of the two chemokines, mainly CCL2 promotes angiogenesis; (3) CCL2 and CCL5 which are expressed by cells of the tumor microenvironment osteoblasts and mesenchymal stem cells play a role in breast metastatic processes. In addition, both chemokines act directly on the tumor cells to promote their pro-malignancy phenotype, by increasing their migratory and invasion-related properties. Together, the overall current information suggests that CCL2 and CCL5 are inflammatory mediators with pro-malignancy activities in breast cancer, and that they should be considered as potential therapeutic targets for the limitation of this disease.
Similar articles
- Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.
Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A. Soria G, et al. Cytokine. 2008 Oct;44(1):191-200. doi: 10.1016/j.cyto.2008.08.002. Epub 2008 Sep 13. Cytokine. 2008. PMID: 18790652 - The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.
Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. Azenshtein E, et al. Cancer Res. 2002 Feb 15;62(4):1093-102. Cancer Res. 2002. PMID: 11861388 - Impact of RANTES, MCP-1 and IL-8 in mast cells.
Castellani ML, De Lutiis MA, Toniato E, Conti F, Felaco P, Fulcheri M, Theoharides TC, Caraffa A, Antinolfi P, Conti P, Cuccurullo C, Ciampoli C, Felaco M, Orso C, Salini V, Cerulli G, Kempuraj D, Tetè S, Shaik B. Castellani ML, et al. J Biol Regul Homeost Agents. 2010 Jan-Mar;24(1):1-6. J Biol Regul Homeost Agents. 2010. PMID: 20385066 Review. - Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy.
Mishra P, Banerjee D, Ben-Baruch A. Mishra P, et al. J Leukoc Biol. 2011 Jan;89(1):31-9. doi: 10.1189/jlb.0310182. Epub 2010 Jul 13. J Leukoc Biol. 2011. PMID: 20628066 Review. - The multifaceted roles of chemokines in malignancy.
Ben-Baruch A. Ben-Baruch A. Cancer Metastasis Rev. 2006 Sep;25(3):357-71. doi: 10.1007/s10555-006-9003-5. Cancer Metastasis Rev. 2006. PMID: 17016763 Review.
Cited by
- Dbl oncogene expression in MCF-10 A epithelial cells disrupts mammary acinar architecture, induces EMT and angiogenic factor secretion.
Vanni C, Ognibene M, Finetti F, Mancini P, Cabodi S, Segalerba D, Torrisi MR, Donnini S, Bosco MC, Varesio L, Eva A. Vanni C, et al. Cell Cycle. 2015;14(9):1426-37. doi: 10.1080/15384101.2015.1021516. Cell Cycle. 2015. PMID: 25723869 Free PMC article. - MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer.
Williams MM, Christenson JL, O'Neill KI, Hafeez SA, Ihle CL, Spoelstra NS, Slansky JE, Richer JK. Williams MM, et al. NPJ Breast Cancer. 2021 May 27;7(1):64. doi: 10.1038/s41523-021-00273-1. NPJ Breast Cancer. 2021. PMID: 34045467 Free PMC article. - Endothelial chemokine receptors as facilitators of tumor cell extravasation?
Hoos A, Wolf MJ, Bauer J, Borsig L, Heikenwalder M. Hoos A, et al. Oncotarget. 2012 Sep;3(9):919-20. doi: 10.18632/oncotarget.672. Oncotarget. 2012. PMID: 23007072 Free PMC article. - Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease.
Lameijer MA, Tang J, Nahrendorf M, Beelen RH, Mulder WJ. Lameijer MA, et al. Expert Rev Mol Diagn. 2013 Jul;13(6):567-80. doi: 10.1586/14737159.2013.819216. Expert Rev Mol Diagn. 2013. PMID: 23895127 Free PMC article. Review. - Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.
Murugaiah V, Agostinis C, Varghese PM, Belmonte B, Vieni S, Alaql FA, Alrokayan SH, Khan HA, Kaur A, Roberts T, Madan T, Bulla R, Kishore U. Murugaiah V, et al. Front Immunol. 2020 Jul 8;11:1171. doi: 10.3389/fimmu.2020.01171. eCollection 2020. Front Immunol. 2020. PMID: 32733438 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous